Suppr超能文献

能否通过坚持抗高血压治疗来促进他汀类药物治疗的依从性?

Can adherence to antihypertensive therapy be used to promote adherence to statin therapy?

作者信息

Chapman Richard H, Pelletier Elise M, Smith Paula J, Roberts Craig S

机构信息

US Health Economics and Outcomes Research, IMS Health, Falls Church, VA, USA;

出版信息

Patient Prefer Adherence. 2009 Nov 3;3:265-75. doi: 10.2147/ppa.s5868.

Abstract

OBJECTIVE

To compare adherence with statin therapy in patients switching to single-pill amlodipine besylate/atorvastatin calcium with patients adding a separate statin to their amlodipine regimen.

METHODS

We identified hypertensive patients prescribed amlodipine who switched to amlodipine/atorvastatin (switch) or added a statin to their amlodipine regimen (add-on) from July 2004 to June 2007. Propensity score matching (1 switch:3 add-on) was applied based on 'nearest neighbor' approach. The primary adherence measure was patients with proportion of days covered (PDC) >/=0.80 at 180 days; secondary measures included mean PDC and persistence. A sensitivity analysis was performed, accounting for total statin/amlodipine exposure.

RESULTS

Among 4556 matched patients (n = 1139 switch; n = 3417 add-on), mean age was 53.9 years and 52.1% were male. After 180 days, adherence with statin therapy was higher for the switch vs add-on cohort (50.8% vs 44.3%; P < 0.001). After adjusting for pre-index amlodipine adherence, the switch cohort was more likely to be adherent than the add-on cohort (odds ratio: 1.64 [95% confidence interval: 1.42 to 1.89]). Persistence was higher in the switch than the add-on cohort (127.6 vs 117 days; P < 0.001).

CONCLUSION

Hypertensive patients taking amlodipine who initiated statin therapy via single-pill amlodipine/atorvastatin were more likely to remain adherent to their statin than patients adding a separate statin to their antihypertensive regimen.

摘要

目的

比较改用氨氯地平苯磺酸盐/阿托伐他汀钙片剂的患者与在氨氯地平治疗方案中加用单独一种他汀类药物的患者对他汀类药物治疗的依从性。

方法

我们确定了2004年7月至2007年6月期间从服用氨氯地平改为服用氨氯地平/阿托伐他汀(转换组)或在氨氯地平治疗方案中加用他汀类药物(加用组)的高血压患者。基于“最近邻”法应用倾向评分匹配(1名转换组患者:3名加用组患者)。主要依从性指标是180天时覆盖天数比例(PDC)≥0.80的患者;次要指标包括平均PDC和持续性。进行了敏感性分析,考虑了他汀类药物/氨氯地平的总暴露量。

结果

在4556名匹配患者中(转换组n = 1139;加用组n = 3417),平均年龄为53.9岁,52.1%为男性。180天后,转换组对他汀类药物治疗的依从性高于加用组(50.8%对44.3%;P < 0.001)。在调整了索引前氨氯地平的依从性后,转换组比加用组更有可能坚持治疗(比值比:1.64 [95%置信区间:1.42至1.89])。转换组的持续性高于加用组(127.6天对117天;P < 0.001)。

结论

服用氨氯地平的高血压患者通过氨氯地平/阿托伐他汀钙片剂开始他汀类药物治疗比在其抗高血压治疗方案中加用单独一种他汀类药物的患者更有可能坚持服用他汀类药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/92da/2778419/64ed9863518b/ppa-3-265f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验